Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

NIH-logo logo-home
COVID-19 Treatment
Guidelines
  • About the Guidelines
    • What's New
    • Table of Contents
    • Guidelines Development
    • Panel Roster
    • Panel Financial Disclosure
    • Guidelines Archive
  • Overview
    • Overview of COVID-19
    • SARS-CoV-2 Testing
    • Prevention of SARS-CoV-2
    • Clinical Spectrum
    • Prioritization of Therapeutics
  • Management
    • Clinical Management of Adults
    • Clinical Management of Children
    • Critical Care for Adults
    • Critical Care for Children
  • Therapies
    • Antivirals, Including Antibody Products
    • Immunomodulators
    • Antithrombotic Therapy
    • Miscellaneous Drugs
    • Supplements
    • Concomitant Medications
  • Special Populations
    • Immunocompromised
    • Cancer
    • Transplant
    • Pregnancy
    • Influenza
    • HIV

Coronavirus Disease 2019 (COVID-19)
Treatment Guidelines

SEE WHAT'S NEW

Credit NIAID-RML

Highlighted Sections

Clinical Management of Adults Summary

This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.

Hospitalized Adults: Therapeutic Management

The Panel provides updated information on the use of abatacept, infliximab, remdesivir, sarilumab, and tofacitinib to treat certain hospitalized adults with COVID-19.

Abatacept

A new section discusses the available clinical data on the use of abatacept, a soluble fusion protein that is used to block T cell activation, to treat certain hospitalized patients with COVID-19.

Clinical Management of Children Summary

The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.

Antithrombotic Therapy

The Panel revised this section based on results from the recently published ANTICOVID trial.

Infliximab

A new section discusses the available clinical data on the use of infliximab, a TNF-alpha inhibitor, to treat certain hospitalized patients with COVID-19.

Clinical Management of Adults Summary

This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.

Hospitalized Adults: Therapeutic Management

The Panel provides updated information on the use of abatacept, infliximab, remdesivir, sarilumab, and tofacitinib to treat certain hospitalized adults with COVID-19.

Abatacept

A new section discusses the available clinical data on the use of abatacept, a soluble fusion protein that is used to block T cell activation, to treat certain hospitalized patients with COVID-19.

Clinical Management of Children Summary

The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.

Antithrombotic Therapy

The Panel revised this section based on results from the recently published ANTICOVID trial.

Infliximab

A new section discusses the available clinical data on the use of infliximab, a TNF-alpha inhibitor, to treat certain hospitalized patients with COVID-19.
Highlighted Sections

Clinical Management of Adults Summary

This section contains tables with the Panel’s recommendations for the therapeutic management of adults with COVID-19.

Hospitalized Adults: Therapeutic Management

The Panel provides updated information on the use of abatacept, infliximab, remdesivir, sarilumab, and tofacitinib to treat certain hospitalized adults with COVID-19.

Abatacept

A new section discusses the available clinical data on the use of abatacept, a soluble fusion protein that is used to block T cell activation, to treat certain hospitalized patients with COVID-19.

Clinical Management of Children Summary

The tables in this section summarize the Panel’s recommendations for the therapeutic management of children with COVID-19 or MIS-C.

Antithrombotic Therapy

The Panel revised this section based on results from the recently published ANTICOVID trial.

Infliximab

A new section discusses the available clinical data on the use of infliximab, a TNF-alpha inhibitor, to treat certain hospitalized patients with COVID-19.
Highlighted Sections
NIH logo
www.covid19treatmentguidelines.nih.gov
An official website of the National Institutes of Health
  1. Contact Us
  2. Office of Inspector General
  1. About NIH
  2. NIH Performance Reporting
  1. Freedom of Information Act
  2. Web Policies and Notices
  1. No FEAR Act Data
  2. Vulnerability Disclosure Policy
Twitter button
  1. Looking for U.S. government information and services?
  2. Visit USA.gov
  3. Site Updated: November 2, 2023